Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8636258 | 0.78 | OPRM1 (0.36) | SPHK1HRH3CHRM1ITGB3ITGA2B | |
| SCHEMBL8636978 | 0.71 | ITGB3 (0.41) | SPHK1CHRM1ITGB3ITGA2BTSHR | |
| SCHEMBL8633916 | 0.67 | ADRB2 (0.35) | CHRM1ITGB3ITGA2B | |
| SCHEMBL8634075 | 0.66 | RORC (0.45) | RORC | |
| SCHEMBL8636259 | 0.65 | NPY2R (0.35) | HRH3ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL8634088 | 0.63 | ITGB3 (0.36) | CHRM1ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL8635011 | 0.62 | ITGB3 (0.48) | HRH3ITGB3ITGA2BTSHRCYP2C9 | |
| Hydrochloric Acid SCHEMBL8837964 | 0.62 | ITGB3 (0.45) | HRH3ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL4378529 | 0.61 | ALDH1A1 (0.62) | TSHRCYP2C9 | |
| SCHEMBL4997015 | 0.61 | NPY2R (0.42) | HRH3TSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5753659-A | ANTICOAGULANTS FOR BLOOD DISORDER, CARDIOVASCULAR DISORDER, THROMBOSIS, | ZENECA LIMITED (GB) | 1998-05-19 | — | — | US | disclosed |